EVO Stock Overview
Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EVO from our risk checks.
Evotec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.60 |
| 52 Week High | €7.77 |
| 52 Week Low | €2.84 |
| Beta | 1.09 |
| 1 Month Change | 2.27% |
| 3 Month Change | -12.41% |
| 1 Year Change | -49.08% |
| 3 Year Change | -73.76% |
| 5 Year Change | -71.73% |
| Change since IPO | 232.56% |
Recent News & Updates
Recent updates
Evotec: Some Recovery Has Come, But Much More Is Expected
Dec 29Evotec: Weak Performance, But Long-Term Potential Is There
Aug 30Evotec: Still A Speculative Buy After A Significant Decline
Apr 24Amgen joins TIAP, Evotec at innovation hub for forming life science companies
Oct 17Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague
Sep 20Evotec to acquire Central Glass Germany to bolster drug substance manufacturing
Aug 25Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303
Aug 10Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance
Jul 06Shareholder Returns
| EVO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 13.2% | -1.8% | -1.1% |
| 1Y | -49.1% | -25.5% | 5.9% |
Return vs Industry: EVO underperformed the US Life Sciences industry which returned -25.6% over the past year.
Return vs Market: EVO underperformed the US Market which returned 5.7% over the past year.
Price Volatility
| EVO volatility | |
|---|---|
| EVO Average Weekly Movement | 7.5% |
| Life Sciences Industry Average Movement | 10.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: EVO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EVO's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 4,740 | Christian Wojczewski | www.evotec.com |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases.
Evotec SE Fundamentals Summary
| EVO fundamental statistics | |
|---|---|
| Market cap | US$1.29b |
| Earnings (TTM) | -US$223.43m |
| Revenue (TTM) | US$908.12m |
1.4x
P/S Ratio-5.8x
P/E RatioIs EVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVO income statement (TTM) | |
|---|---|
| Revenue | €796.97m |
| Cost of Revenue | €682.09m |
| Gross Profit | €114.88m |
| Other Expenses | €310.96m |
| Earnings | -€196.08m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 06, 2025
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 14.41% |
| Net Profit Margin | -24.60% |
| Debt/Equity Ratio | 30.2% |
How did EVO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 08:07 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evotec SE is covered by 30 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | Berenberg |
| Michael Ryskin | BofA Global Research |
| Alexandru Cogut | Bryan Garnier & Co |